Novo Nordisk A/S (NYSE:NVO) Stake Lessened by Venturi Wealth Management LLC

Venturi Wealth Management LLC reduced its holdings in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) by 17.7% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 30,629 shares of the company's stock after selling 6,603 shares during the quarter. Venturi Wealth Management LLC's holdings in Novo Nordisk A/S were worth $2,635,000 as of its most recent SEC filing.

Other hedge funds have also made changes to their positions in the company. Rosenberg Matthew Hamilton raised its holdings in Novo Nordisk A/S by 2.5% in the third quarter. Rosenberg Matthew Hamilton now owns 3,812 shares of the company's stock valued at $454,000 after acquiring an additional 94 shares in the last quarter. Spinnaker Trust increased its position in shares of Novo Nordisk A/S by 1.1% in the 3rd quarter. Spinnaker Trust now owns 9,615 shares of the company's stock worth $1,145,000 after purchasing an additional 100 shares during the last quarter. Marco Investment Management LLC raised its stake in shares of Novo Nordisk A/S by 1.5% in the 3rd quarter. Marco Investment Management LLC now owns 6,702 shares of the company's stock valued at $798,000 after purchasing an additional 100 shares in the last quarter. Carr Financial Group Corp lifted its position in shares of Novo Nordisk A/S by 5.1% during the third quarter. Carr Financial Group Corp now owns 2,100 shares of the company's stock worth $250,000 after purchasing an additional 101 shares during the last quarter. Finally, Menard Financial Group LLC grew its stake in Novo Nordisk A/S by 0.8% in the third quarter. Menard Financial Group LLC now owns 12,283 shares of the company's stock worth $1,463,000 after purchasing an additional 102 shares in the last quarter. Institutional investors and hedge funds own 11.54% of the company's stock.

Novo Nordisk A/S Stock Performance

NYSE NVO traded up $4.33 during trading hours on Friday, hitting $88.07. The company had a trading volume of 15,117,993 shares, compared to its average volume of 9,263,626. The company has a quick ratio of 0.55, a current ratio of 0.74 and a debt-to-equity ratio of 0.62. The firm has a market cap of $395.19 billion, a P/E ratio of 26.77, a price-to-earnings-growth ratio of 0.90 and a beta of 0.45. Novo Nordisk A/S has a fifty-two week low of $77.82 and a fifty-two week high of $148.15. The business has a fifty day simple moving average of $86.01 and a 200-day simple moving average of $108.22.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last issued its quarterly earnings data on Wednesday, February 5th. The company reported $0.91 earnings per share for the quarter, beating the consensus estimate of $0.88 by $0.03. Novo Nordisk A/S had a net margin of 34.81% and a return on equity of 84.68%. Equities analysts predict that Novo Nordisk A/S will post 3.84 EPS for the current year.

Novo Nordisk A/S Increases Dividend

The firm also recently disclosed a semi-annual dividend, which will be paid on Tuesday, April 8th. Investors of record on Monday, March 31st will be issued a $0.7874 dividend. This represents a yield of 1.2%. This is a positive change from Novo Nordisk A/S's previous semi-annual dividend of $0.51. The ex-dividend date of this dividend is Monday, March 31st. Novo Nordisk A/S's dividend payout ratio is 47.72%.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on NVO shares. Morgan Stanley began coverage on Novo Nordisk A/S in a research note on Wednesday, February 12th. They set an "equal weight" rating on the stock. BMO Capital Markets dropped their price target on Novo Nordisk A/S from $156.00 to $105.00 and set an "outperform" rating on the stock in a research report on Monday, December 23rd. BNP Paribas raised shares of Novo Nordisk A/S to a "strong-buy" rating in a report on Monday, December 2nd. Cantor Fitzgerald reissued an "overweight" rating and set a $160.00 target price on shares of Novo Nordisk A/S in a report on Wednesday, November 6th. Finally, Sanford C. Bernstein upgraded shares of Novo Nordisk A/S from an "underperform" rating to a "market perform" rating in a research report on Monday, January 6th. Two investment analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $145.25.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.